Sergey Karakashev

1.3k total citations
16 papers, 778 citations indexed

About

Sergey Karakashev is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sergey Karakashev has authored 16 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Sergey Karakashev's work include RNA modifications and cancer (5 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer-related Molecular Pathways (4 papers). Sergey Karakashev is often cited by papers focused on RNA modifications and cancer (5 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer-related Molecular Pathways (4 papers). Sergey Karakashev collaborates with scholars based in United States, Russia and France. Sergey Karakashev's co-authors include Mauricio J. Reginato, Rugang Zhang, Andrew V. Kossenkov, Nail Fatkhutdinov, Hengrui Zhu, Takeshi Fukumoto, Shuai Wu, Stéphanie Jean, Benjamin G. Bitler and David W. Speicher and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Cancer Cell.

In The Last Decade

Sergey Karakashev

16 papers receiving 776 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sergey Karakashev United States	10	636	270	203	59	55	16	778
Ahrum Min South Korea	16	634 1.0×	635 2.4×	123 0.6×	78 1.3×	34 0.6×	36	957
Samantha M. Tienda United States	5	874 1.4×	209 0.8×	447 2.2×	21 0.4×	95 1.7×	7	1.1k
Junli Deng China	7	332 0.5×	198 0.7×	180 0.9×	41 0.7×	51 0.9×	8	498
Federica Guffanti Italy	13	374 0.6×	300 1.1×	143 0.7×	73 1.2×	115 2.1×	33	577
Shane W. O’Brien United States	12	401 0.6×	188 0.7×	88 0.4×	44 0.7×	69 1.3×	14	602
Andrea Ghelli Luserna di Rorà Italy	13	513 0.8×	303 1.1×	98 0.5×	73 1.2×	14 0.3×	38	735
Takafumi Kuroda Japan	14	439 0.7×	245 0.9×	172 0.8×	104 1.8×	127 2.3×	26	694
Sabrina Giavara Italy	4	1.1k 1.7×	826 3.1×	168 0.8×	59 1.0×	117 2.1×	5	1.4k
Maureen M. Hattersley United States	15	551 0.9×	344 1.3×	83 0.4×	36 0.6×	20 0.4×	27	821

Countries citing papers authored by Sergey Karakashev

Since Specialization

Citations

This map shows the geographic impact of Sergey Karakashev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergey Karakashev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergey Karakashev more than expected).

Fields of papers citing papers by Sergey Karakashev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergey Karakashev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergey Karakashev. The network helps show where Sergey Karakashev may publish in the future.

Co-authorship network of co-authors of Sergey Karakashev

This figure shows the co-authorship network connecting the top 25 collaborators of Sergey Karakashev. A scholar is included among the top collaborators of Sergey Karakashev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergey Karakashev. Sergey Karakashev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Karakashev, Sergey, et al.. (2024). Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy. Journal of Cellular Physiology. 240(1). e31495–e31495. 1 indexed citations

Lin, Jianhuang, Wei Zhou, Andrew V. Kossenkov, et al.. (2022). KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research. 10(8). 1028–1038. 9 indexed citations

Lin, Jianhuang, Heng Liu, Takeshi Fukumoto, et al.. (2021). Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nature Communications. 12(1). 5321–5321. 37 indexed citations

Karakashev, Sergey & Rugang Zhang. (2021). Mouse models of epithelial ovarian cancer for preclinical studies. 动物学研究. 42(2). 153–160. 17 indexed citations

Karakashev, Sergey, Takeshi Fukumoto, Bo Zhao, et al.. (2020). EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell. 37(2). 157–167.e6. 97 indexed citations

Karakashev, Sergey & Rugang Zhang. (2020). Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors. Molecular & Cellular Oncology. 7(4). 1760675–1760675. 5 indexed citations

Fukumoto, Takeshi, Hengrui Zhu, Sergey Karakashev, et al.. (2019). Abstract NT-093: THE N6-METHYLATION OF ADENOSINE (M6A) IN FZD10 MRNA CONTRIBUTES TO RESISTANCE TO PARP INHIBITOR. Clinical Cancer Research. 25(22_Supplement). NT–93. 1 indexed citations

Fukumoto, Takeshi, Hengrui Zhu, Timothy Nacarelli, et al.. (2019). N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance. Cancer Research. 79(11). 2812–2820. 141 indexed citations

Karakashev, Sergey, Hengrui Zhu, Shuai Wu, et al.. (2018). CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9(1). 631–631. 76 indexed citations

10.

Fukumoto, Takeshi, Pyoung Hwa Park, Shuai Wu, et al.. (2018). Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports. 22(13). 3393–3400. 77 indexed citations

11.

Karakashev, Sergey, Hengrui Zhu, Yuhki Yokoyama, et al.. (2017). BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports. 21(12). 3398–3405. 134 indexed citations

12.

Kossenkov, Andrew V., Sergey Karakashev, Fiona Simpkins, et al.. (2017). BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. 1 indexed citations

13.

Reginato, Mauricio J. & Sergey Karakashev. (2015). Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Management and Research. 7. 253–253. 82 indexed citations

14.

Karakashev, Sergey & Mauricio J. Reginato. (2015). Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget. 6(4). 1967–1980. 40 indexed citations

15.

Karakashev, Sergey. (2014). Abstract 1824: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2. Cancer Research. 74(19_Supplement). 1824–1824. 1 indexed citations

16.

Whelan, Kelly A., Luciana P. Schwab, Sergey Karakashev, et al.. (2013). The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance. Journal of Biological Chemistry. 288(22). 15865–15877. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact